PT - JOURNAL ARTICLE AU - Neelathi, Uma M. AU - Ullah, Ehsan AU - George, Aman AU - Maftei, Mara I. AU - Boobalan, Elangovan AU - Sanchez-Mendoza, Daniel AU - Adams, Chloe AU - McGaughey, David AU - Sergeev, Yuri V. AU - Rawi, Ranya AI AU - Naik, Amelia AU - Bender, Chelsea AU - Maumenee, Irene H. AU - Michaelides, Michel AU - Tan, Tun Giap AU - Lin, Siying AU - Villasmil, Rafael AU - Blain, Delphine AU - Hufnagel, Robert B. AU - Arno, Gavin AU - Young, Rodrigo M. AU - Guan, Bin AU - Brooks, Brian P. TI - Variants in <em>NR6A1</em> cause a novel oculo-vertebral-renal (OVR) syndrome AID - 10.1101/2024.11.09.24316578 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.09.24316578 4099 - http://medrxiv.org/content/early/2024/11/11/2024.11.09.24316578.short 4100 - http://medrxiv.org/content/early/2024/11/11/2024.11.09.24316578.full AB - Colobomatous microphthalmia is a potentially blinding congenital ocular malformation that can present either in isolation or together with other syndromic features. Despite a strong genetic component to disease, many cases lack a molecular diagnosis. We describe a novel autosomal dominant oculo-vertebral-renal (OVR) syndrome in six independent families characterized by colobomatous microphthalmia, missing vertebrae and congenital kidney abnormalities. Genome sequencing identified six rare variants in the orphan nuclear receptor gene NR6A1 in these families. We performed in silico, cellular and zebrafish experiments to demonstrate the NR6A1 variants were pathogenic or likely pathogenic for OVR syndrome. Knockdown of either or both zebrafish paralogs of NR6A1 results in abnormal eye and somite development, which was rescued by wild-type but not variant NR6A1 mRNA. Illustrating the power of genomic ascertainment in medicine, our study establishes NR6A1 as a critical factor in eye and vertebral development and a pleiotropic gene responsible for OVR syndrome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Intramural Research Program of the NIH. GA is supported by a Fight For Sight (UK) Early Career Investigator Award (5045/46), the National Institute of Health Research Biomedical Research Centre (NIHR-BRC) at Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, and Moorfields Eye Charity (Stephen and Elizabeth Archer in memory of Marion Woods) and NIH-P20GM139769. RY was supported by the Moorfields Eye Charity Career Development Award and Springboard (GR001155 and GR001210), Medical Research Council (MR/X001067/1) and FODNECYT (1221843). MIM was supported by Moorfields Eye Charity PhD Studentship (GR001661).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of National Institutes of Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript and UK100KGP data was managed by Genomics Data England Limited.